Literature DB >> 21326262

Physician barriers to incorporating pharmacogenetic treatment strategies for nicotine dependence into clinical practice.

R A Schnoll1, A E Shields.   

Abstract

Advances in genomics research may improve health outcomes by tailoring treatment according to patients' genetic profiles. The treatment of nicotine dependence, in particular, may soon encompass pharmacogenetic treatment models. Realizing the benefits of such treatment strategies may depend on physicians' preparedness to incorporate genetic testing into clinical practice. This article describes barriers to clinical integration of pharmacogenetic treatments that will need to be addressed to realize the benefits of individualized smoking-cessation treatment.

Entities:  

Mesh：

Year:  2011        PMID： 21326262      PMCID： PMC3184286          DOI： 10.1038/clpt.2010.267

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  4 in total

1.  Primary care physicians' concerns about offering a genetic test to tailor smoking cessation treatment.

Authors:  Douglas E Levy; Emily J Youatt; Alexandra E Shields
Journal:  Genet Med       Date:  2007-12       Impact factor: 8.822

Review 2.  Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready?

Authors:  A E Shields; C Lerman
Journal:  Clin Pharmacol Ther       Date:  2008-03-05       Impact factor: 6.875

3.  Barriers to translating emerging genetic research on smoking into clinical practice. Perspectives of primary care physicians.

Authors:  Alexandra E Shields; David Blumenthal; Kevin B Weiss; Catherine B Comstock; Douglas Currivan; Caryn Lerman
Journal:  J Gen Intern Med       Date:  2005-02       Impact factor: 5.128

4.  Primary care physicians' willingness to offer a new genetic test to tailor smoking treatment, according to test characteristics.

Authors:  Alexandra E Shields; Douglas E Levy; David Blumenthal; Douglas Currivan; Mary McGinn-Shapiro; Kevin B Weiss; Recai Yucel; Caryn Lerman
Journal:  Nicotine Tob Res       Date:  2008-06       Impact factor: 4.244
  4 in total
  7 in total

1.  Pharmacogenetic testing: Current Evidence of Clinical Utility.

Authors:  Jivan Moaddeb; Susanne B Haga
Journal:  Ther Adv Drug Saf       Date:  2013-08-01

2.  On the readiness of physicians for pharmacogenomics testing: an empirical assessment.

Authors:  N Amara; J Blouin-Bougie; D Bouthillier; J Simard
Journal:  Pharmacogenomics J       Date:  2017-06-13       Impact factor: 3.550

Review 3.  Biomarkers to optimize the treatment of nicotine dependence.

Authors:  Robert A Schnoll; Frank T Leone
Journal:  Biomark Med       Date:  2011-12       Impact factor: 2.851

4.  Primary care physicians' knowledge of and experience with pharmacogenetic testing.

Authors:  S B Haga; W Burke; G S Ginsburg; R Mills; R Agans
Journal:  Clin Genet       Date:  2012-07-03       Impact factor: 4.438

5.  Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system.

Authors:  Samuel G Johnson; Paul B Shaw; Thomas Delate; Deanna L Kurz; Dylon Gregg; John C Darnell; Christina L Aquilante
Journal:  Pharm Pract (Granada)       Date:  2017-06-30

Review 6.  Barriers to genetic testing in clinical psychiatry and ways to overcome them: from clinicians' attitudes to sociocultural differences between patients across the globe.

Authors:  Justo Pinzón-Espinosa; Marte van der Horst; Janneke Zinkstok; Jehannine Austin; Cora Aalfs; Albert Batalla; Patrick Sullivan; Jacob Vorstman; Jurjen J Luykx
Journal:  Transl Psychiatry       Date:  2022-10-11       Impact factor: 7.989

Review 7.  Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds.

Authors:  Christian S Hendershot
Journal:  Addict Sci Clin Pract       Date:  2014-09-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.